Jacob Groenendyk
Internal Medicine · Chicago, ILNPI 1639638505
Payments from drug & device makers
Across 100 payments — averaging $249.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$9K
- Medtronic$7K
- Abbott$6K
- Biotronik Inc.$1K
- EBR Systems, Inc.$325
- Boehringer Ingelheim$271
- plus $897 from 15 others
What the payments were for
- Grants$16,25065%
- Travel & lodging$2,93212%
- Food & beverage$5,32721%
- Education$4352%
- Entertainment$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 20 | $9,258 |
| Medtronic | 5 | $6,616 |
| Abbott | 31 | $6,127 |
| Biotronik Inc. | 9 | $1,481 |
| EBR Systems, Inc. | 1 | $325 |
| Boehringer Ingelheim | 9 | $271 |
| Heartflow, Inc. | 1 | $201 |
| Philips North America LLC | 1 | $118 |
| AstraZeneca | 4 | $99 |
| Novartis | 3 | $84 |
| Biosense Webster, Inc. | 1 | $74 |
| Lantheus Medical Imaging, Inc. | 2 | $49 |
| Pfizer | 3 | $48 |
| Chiesi USA, Inc. | 2 | $36 |
| Johnson & Johnson | 1 | $34 |
| Stereotaxis Inc | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Cardiva Medical, Inc. | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Abiomed | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM MRI S-ICD$5,000
- GENERAL - THERAPIES$3,856
- TACTICATH$2,500
- ASSURITY$2,000
- MitraClip$500
- BioMonitor$456
- ENSITE$253
- FFRct$201
- Acticor 7 VR-T DX$179
- ACCENT$166
- Farapulse$156
- JARDIANCE$124
- AVEIR$118
- (9520) IGT Devices Undivided$118
- GALLANT$102
How this compares
$24,975 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $20,011 |
| Metoprolol Succinate | 29 | $388 |
| Ezetimibe | 15 | $327 |
| Atorvastatin Calcium | 15 | $156 |
| Losartan Potassium | 15 | $117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $20,01121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.